Molecular Pathways and Clinical Applications of Probiotics as Effective Supporters of Intestinal, Neurologic, and Cardiovascular Health: a Narrative Review

This narrative review synthesizes what is currently known about how probiotics — live beneficial bacteria — work at the molecular level and what they can do clinically across three major body systems: the gut, the brain, and the heart. For the gut, specific strains strengthen the physical lining of the intestine and calm inflammation, helping conditions like irritable bowel syndrome and antibiotic-associated diarrhea. For the brain, so-called 'psychobiotic' strains appear to influence mood and cognition by tweaking the production of neurotransmitters and dampening stress-hormone pathways. For the heart, pooled data from more than 30 randomized trials show modest but consistent reductions in LDL cholesterol and blood pressure. The review also flags that while probiotics are safe for most healthy people, rare but serious side effects can occur in immunocompromised or critically ill patients. The authors conclude that strain choice, dose, and patient profile all matter enormously, and that precision-medicine approaches — guided by multi-omics profiling — are needed before probiotics can be deployed as reliable therapeutics.

• Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12 upregulate tight-junction proteins (occludin, claudin-1), restore epithelial barrier integrity, and shift cytokine balance toward anti-inflammation (↑IL-10, ↓TNF-α and IL-6) in intestinal conditions including IBS, constipation, and antibiotic-associated diarrhea.
• Psychobiotic strains (L. rhamnosus JB-1, B. longum 1714, and the L. helveticus R0052 + B. longum R0175 combination) modulate GABA and serotonin synthesis, suppress HPA-axis hyperactivity, and reduce neuroinflammation, with reported benefits for anxiety, stress resilience, cognitive function, and slowing brain-atrophy progression in mild cognitive impairment and Alzheimer's disease.
• Meta-analyses of 30+ RCTs show probiotic supplementation (notably L. acidophilus, L. plantarum, B. longum) lowers total and LDL cholesterol by approximately 7–10 mg/dL via bile-salt hydrolase activity, SCFA-mediated GPR signaling, and direct cholesterol assimilation, and reduces systolic blood pressure by 2–4 mmHg through anti-inflammatory and endothelial-function pathways.
• Rare but clinically meaningful adverse events — including bacteremia, D-lactic acidosis, and horizontal gene transfer of antibiotic-resistance genes — have been documented in immunocompromised or critically ill individuals, emphasizing the need for individualized risk-benefit assessment and robust adverse-event surveillance frameworks.

This is a narrative review; no primary data were collected. The authors synthesized published literature — including randomized controlled trials, meta-analyses, and mechanistic studies — covering three health domains: intestinal, neurologic, and cardiovascular. No formal systematic search protocol, PRISMA flow diagram, or quantitative meta-analytic pooling is described, consistent with the narrative review format. The scope spans multiple probiotic genera (Lactobacillus, Bifidobacterium) and multiple clinical endpoints, with safety data integrated from case reports and surveillance literature.

As a narrative review without a registered protocol or systematic search strategy, the article is susceptible to selection bias and cannot quantify heterogeneity across included studies the way a formal meta-analysis would. The breadth of the review (three organ systems, dozens of strains, multiple conditions) necessarily limits mechanistic depth for any single strain-disease pairing. Most underlying RCTs are short-duration and use heterogeneous probiotic formulations, doses, and outcome measures, making it difficult to derive actionable clinical guidance. Future head-to-head trials with standardized strain formulations, multi-omics phenotyping of participants, and pre-registered adverse-event monitoring protocols would directly address these gaps.

This review extends [§155] (Saccharomyces boulardii CNCM I-745 on intestinal barrier function) by providing a broader mechanistic framework — covering tight-junction upregulation, cytokine modulation, and neurotransmitter signaling — that contextualizes single-strain barrier studies within a multi-system perspective. It parallels [§142] (gut microbiome-mediated bioactive ingredients in fermented products), sharing the emphasis on SCFA signaling, bile-salt hydrolase activity, and microbiome-host crosstalk as unifying mechanistic threads, though the present review centers on defined probiotic strains rather than complex fermented matrices. The cardiovascular and metabolic findings complement [§157] (Akkermansia muciniphila in pediatric obesity), where a single next-generation probiotic strain is evaluated for cardiometabolic endpoints, illustrating how the multi-strain narrative synthesis here provides the mechanistic backdrop for such focused single-strain trials. The immunomodulatory pathways described — particularly IL-10 upregulation and NF-κB suppression — also align with mechanisms reported in [§151] (Bifidobacterium bifidum BGN4 in cyclophosphamide-induced immunosuppression), reinforcing the cross-study consistency of probiotic-driven immune regulation.

• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Directly investigates intestinal barrier function with a single yeast probiotic strain, providing focused mechanistic and clinical data that can be compared against the multi-strain tight-junction findings summarized in this review.
• AKK Study in Improving Obesity and Metabolic Status in Children and Adolescents
  Examines a next-generation probiotic (Akkermansia muciniphila) for cardiometabolic outcomes in children, offering a narrower, single-strain counterpoint to the broad multi-strain cardiovascular meta-analytic evidence synthesized here.
• Immunomodulatory Effects of Bifidobacterium bifidum BGN4 in Cyclophosphamide-induced Immunosuppressed Mice via Activation of NK Cells and Macrophages
  Reports Bifidobacterium-specific immunomodulatory mechanisms (NF-κB, cytokine pathways) in an animal model, allowing comparison of whether the molecular pathways this review attributes to Bifidobacterium strains are consistent across experimental contexts.
• Probiotic Intervention on the Development of Allergic Diseases in Infants Exposed to Antibiotics Early in Life
  Focuses specifically on probiotic intervention in infants exposed to early-life antibiotics — a clinically important subpopulation — complementing the antibiotic-associated diarrhea and microbiome-restoration findings discussed in this review.
• Gut microbiome-mediated bioactive ingredients and health benefits of medicinal and edible fermented products: A comprehensive review
  Covers overlapping mechanisms (SCFA signaling, gut microbiome modulation, bioactive compound pathways) but from the angle of fermented food products rather than defined probiotic strains, enabling a useful comparison of delivery-vehicle effects on shared molecular targets.